These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 34812901)

  • 1. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.
    Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA
    Psychopharmacology (Berl); 2022 Jan; 239(1):15-33. PubMed ID: 34812901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
    Schipper S; Nigam K; Schmid Y; Piechotta V; Ljuslin M; Beaussant Y; Schwarzer G; Boehlke C
    Cochrane Database Syst Rev; 2024 Sep; 9(9):CD015383. PubMed ID: 39260823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Psychedelics for existential distress in terminally ill patients].
    Schimmel N; Breeksema JJ; Veraart JKE; van den Brink W; Schoevers RA
    Tijdschr Psychiatr; 2020; 62(8):659-668. PubMed ID: 32816294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.
    Reiche S; Hermle L; Gutwinski S; Jungaberle H; Gasser P; Majić T
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():1-10. PubMed ID: 28947181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classical psychedelics for the treatment of depression and anxiety: A systematic review.
    Muttoni S; Ardissino M; John C
    J Affect Disord; 2019 Nov; 258():11-24. PubMed ID: 31382100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
    Ross S
    Int Rev Psychiatry; 2018 Aug; 30(4):317-330. PubMed ID: 30102082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
    Ross S; Bossis A; Guss J; Agin-Liebes G; Malone T; Cohen B; Mennenga SE; Belser A; Kalliontzi K; Babb J; Su Z; Corby P; Schmidt BL
    J Psychopharmacol; 2016 Dec; 30(12):1165-1180. PubMed ID: 27909164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taking Psychedelics Seriously.
    Byock I
    J Palliat Med; 2018 Apr; 21(4):417-421. PubMed ID: 29356590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review.
    Kim A; Halton B; Shah A; Seecof OM; Ross S
    Ann Palliat Med; 2024 Nov; 13(6):1490-1501. PubMed ID: 39168642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care.
    Ross S; Agrawal M; Griffiths RR; Grob C; Berger A; Henningfield JE
    Neuropharmacology; 2022 Sep; 216():109174. PubMed ID: 35772523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
    Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
    Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of psychedelic medicine: current status and future directions.
    Wsół A
    Pharmacol Rep; 2023 Dec; 75(6):1362-1380. PubMed ID: 37874530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
    Moreton SG; Szalla L; Menzies RE; Arena AF
    Psychopharmacology (Berl); 2020 Jan; 237(1):21-32. PubMed ID: 31784805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.
    Jing X; Hoeh NR; Menkes DB
    Palliat Support Care; 2023 Aug; 21(4):697-704. PubMed ID: 37334486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.